UK court finds SEROQUEL XR® formulation patent invalid
22 March 2012 | By AstraZeneca
The High Court in the UK has rendered its opinion on the formulation patent protecting SEROQUEL XR®...
List view / Grid view
22 March 2012 | By AstraZeneca
The High Court in the UK has rendered its opinion on the formulation patent protecting SEROQUEL XR®...
22 March 2012 | By GlaxoSmithKline
Up to 1,000 new jobs created...
21 March 2012 | By Lundbeck
Lundbeck has appointed Jacob Tolstrup as new vice president with responsibility for the company's business development...
21 March 2012 | By Abbott
AbbVie the new, independent research-based pharmaceutical company...
Freddy White, European Pharmaceutical Review speaks to Marketing Director for Informatics at Thermo Fisher Scientific, Susan Najjar...
20 March 2012 | By Merck
"Merck remains confident in the potential of the investigational agent ridaforolimus..."
20 March 2012 | By GlaxoSmithKline
“Treatment options for patients with advanced soft tissue sarcoma are limited..."
20 March 2012 | By Abbott
Abbott announced the company's schedule of key presentations...
20 March 2012 | By AstraZeneca
Top-line results from the remaining Phase III studies - announced...
20 March 2012 | By Merck
Collaboration advances Merck's commitment to fighting disease to help the world be well...
19 March 2012 | By NICE
Pradaxa® must now be made available for use by the UK National Health Service (NHS)...
19 March 2012 | By FDA
The U.S. FDA approved the first generic versions of Boniva (ibandronate) tablets...
19 March 2012 | By Merck
Calibr presents a new paradigm for academic-industry cooperation...
Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA® (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa (HS).
19 March 2012 | By Takeda Pharmaceutical Company Limited
Results presented at 76th Annual Scientific Meeting of the Japanese Circulation Society in Fukuoka...